Abstract:Although the role of orthotopic liver transplantation (OLT) in the treatment of hepatocellular carcinoma (HCC) has improved over the years, tumor recurrence is still a major imitation of long-term survival even after radical transplantation treatment.1Okuda K. Ohtsuki T. Obata H. et al.Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients.Cancer. 1985; 56: 918-928Crossref PubMed Scopus (1717) Google Scholar Thoracic metastasis is the most common site of extrahepatic spreads. The role of surgery for thoracic metastasis is not known, and until now there have been few reports about surgical resection for thoracic HCC metastasis after liver transplantation. We evaluate the surgical efficacy in the treatment of thoracic HCC recurrence after OLT. Between October of 2003 and September of 2007, 5 patients who had undergone OLT for HCC demonstrated resectable thoracic HCC recurrence and were admitted to the Department of Thoracic and Cardiovascular Surgery without other identifiable recurrence foci. Thoracic recurrence was located in the right lower lobe and the upper lobe in 1 patient, the right lower lobe in 1 patient, the fourth to sixth right costal cartilage and the right lower lobe in 1 patient, the middle lobe in 1 patient, and the right upper lobe in 1 patient. They underwent standard lobectomy or wedge resection for thoracic recurrence. The specimen pathology showed all low differentiated metastatic HCC, except a benign nodule of the right lower lobe in the patient with recurrence in the costal cartilage. After surgical resection, no patient received chemotherapy or other adjuvant treatments. Patients were followed up at interval with laboratory analysis and whole body scan for physical conditions and a second recurrence. HCC recurrence developed in the left adrenal gland in 1 patient 6 months after right lower lobectomy. Left adrenal gland resection was performed under laparoscopic surgery, and the pathology revealed low differentiated metastatic HCC. The other 4 patients have no recurrence, and all 5 patients are currently alive. The time from transplant to diagnosis of thoracic recurrence ranged from 8 to 33 months, with an average period of 18.6 months. The survival time from transplant ranged from 16 to 85 months, with a mean time of 37.4 months. The survival time from thoracic resection ranged from 3 to 53 months, with an average time of 17.8 months. The study was retrospective and approved by all 5 patients. All thoracic surgical management, survival time, and other clinical parameters are reviewed in Table 1.Table 1Characteristics of patients and data of recurrence, metastasectomy, survival timePatient12345GenderMaleMaleMaleMaleMaleAge, y4966476337Thoracic recurrence LocationRUL, RLLRLLRCC, RLLRMLRUL Size (cm)1, 23.55, 0.531 ResectionWedgeLobectomyRib resection, LobectomyWedgeWedge Tumor differentiation gradeLow, lowLowLow, benignLowLow Postresection treatmentNoNoNoNoNoSecondary recurrenceNoYesNoNoNo Location—Left adrenal gland——— Size (cm)—3——— Resection—Laparoscope——— Tumor differentiation grade—Low——— Postresection treatment—No———AliveYesYesYesYesYesTime from transplant (mo) to thoracic recurrence323312811 to secondary recurrence—39———Survival time from TRR (mo)5316893RUL, Right upper lobe; RLL, right lower lobe; RCC, right costal cartilage; RML, right middle lobe; TRR, thoracic recurrence resection. Open table in a new tab RUL, Right upper lobe; RLL, right lower lobe; RCC, right costal cartilage; RML, right middle lobe; TRR, thoracic recurrence resection. Liver transplantation was considered as radical surgery macroscopically (the tumor is resected completely and there is no residual tumor tissue from surgeon's eye and radiography) for patients with HCC. However, tumor recurrence was the major limitation of long-term survival after liver transplantation. Although intrahepatic recurrence predominated, the most common location of extrahepatic metastasis was the thorax.2Si M.S. Amersi F. Golish S.R. Prevalence of metastases in hepatocellular carcinoma: risk factors and impact on survival.Am Surg. 2003; 69: 879-885PubMed Google Scholar Survival for patients with recurrence was significantly shorter than for patients undergoing transplantation for HCC without recurrence. Thoracic recurrence was mainly detected by biochemical and radiographic evidence. Increased alpha-fetoprotein level was generally an early key indicator for any advanced radiographic evidence of HCC recurrence. Enhanced computed tomography, ultrasonography, positron emission tomography, and radionuclide bone imaging were also important as routine initial or advanced screening for recurrence evidence. Although some studies have shown that only adjuvant treatments for posttransplant HCC recurrence without surgical resection may be good to increase survival, a better benefit may be obtained from metastasectomy.3Bates M.J. Farkas E. Taylor D. McFadden P.M. Pulmonary resection of metastatic hepatocellular carcinoma after liver transplantation.Ann Thorac Surg. 2008; 85: 412-415Abstract Full Text Full Text PDF PubMed Scopus (32) Google Scholar The type of surgical resection was based on the patients' anatomic and physiologic considerations. Radical lobectomy was preferred, and wedge resection was considered according to the recurrence anatomic site, numbers, pulmonary function, and even the request of the patients. All 5 patients are currently alive, and the average survival time from thoracic resection is 17.8 months, which is similar to the results of previous reports.3Bates M.J. Farkas E. Taylor D. McFadden P.M. Pulmonary resection of metastatic hepatocellular carcinoma after liver transplantation.Ann Thorac Surg. 2008; 85: 412-415Abstract Full Text Full Text PDF PubMed Scopus (32) Google Scholar Although the size of our study population was small, the survival time in these patients is encouraging. A larger study may be necessary to assess the possible benefits of surgical resection and surgical types for resectable thoracic metastasis after liver transplantation for HCC. These aims should be accomplished with advanced investigation in a larger population and a longer follow-up for similar patients. There have been few reports about surgical resection for thoracic metastasis after liver transplantation for HCC. In our series, metastasectomy for resectable thoracic HCC recurrence after liver transplantation was encouraging and is suggested as a reasonable treatment.

Clinical Benefits of Neoadjuvant Radiotherapy on the Postoperative Recurrence of Centrally Located Hepatocellular Carcinoma: A Real-World Evidence Based on Phase II Clinical Trial

Surgical Resection of Resectable Thoracic Metastatic Hepatocellular Carcinoma after Liver Transplantation

Surgical Resection Plus Radiofrequency Ablation Versus Radical Surgery for Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma: A Nonrandomized Controlled Trial.

Long-term outcome of adjuvant radiotherapy upon postoperative relapse of centrally located hepatocellular carcinoma: a real-world study

Adjuvant Radiotherapy in Centrally Located Hepatocellular Carcinomas after Hepatectomy with Narrow Margin (<1 Cm): a Prospective Randomized Study.

Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy: A 10-year real-world evidence

An Overview of Traditional Chinese Medicine in the Treatment After Radical Resection of Hepatocellular Carcinoma

Long-Term Outcome of Centrally Located Hepatocellular Carcinomas Treated by Radical Resection Combined With Intraoperative Electron Radiotherapy (IOERT)

Stereotactic Body Radiation Therapy in Patients with Centrally Located Hepatocellular Carcinoma: A Retrospective, Single-Arm, Multi-Center Study

Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.

Clinical analysis of surgical resection for centrally located hepatocellular carcinoma

Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy

Impact of Neoadjuvant Immunotherapy on Recurrence-Free Survival in Patients with High-Risk Localized HCC

Value of Postoperative Radiotherapy for Centrally Located Hepatocellular Carcinoma

Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma

Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System

Phase 2 Study of Adjuvant Radiotherapy Following Narrow‐Margin Hepatectomy in Patients With HCC

Benefit of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score-Matched Study

Adjuvant radiotherapy after curative resection of hepatocellular carcinoma with narrow margin (≤1 cm): A phase 2, multicenter, randomized controlled trial.

A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage.